Bi-Specific MAbS Market Trends, Drivers, and Regional Analysis 2025–2029

Uncover key drivers, emerging technologies, and competitive movements shaping the bi-specific mabs market from 2025–2034 with trusted insights from The Business Research Company

How Is The Bi-Specific MAbS Market Size Expected To Expand Over 2029-2034?

The size of the bi-specific MAbS market has experienced rapid growth in recent years. Projections indicate it will expand from $7.83 billion in 2024 to $9.05 billion in 2025, achieving a compound annual growth rate (CAGR) of 15.5%. This historical growth can be ascribed to elements like increased healthcare expenditure, augmented funding, and various government initiatives.

The bi-specific MAbS market size is anticipated to undergo significant expansion in the upcoming years. It is predicted to attain $14.89 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 13.3%. This growth during the forecast period can be attributed to the rising incidence of cancer, an expanding aging demographic, and an increased prevalence of chronic diseases. Prominent trends for the forecast period involve a concentrated effort on technological advancements, product innovation, the integration of artificial intelligence, substantial investment in targeted and combination therapy, and the establishment of strategic partnerships.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

Which Market Factors Are Fueling The Bi-Specific MAbS Industry Growth?

The projected expansion of the bispecific monoclonal antibodies market throughout the forecast period is expected to be driven by the growing incidence of cancer and other chronic ailments. These antibodies are engineered to address a range of conditions, including diverse cancers, infectious illnesses, central nervous system conditions, and autoimmune diseases. Their superior efficacy compared to conventional monoclonal antibodies (moAbs) stems from their ability to target multiple (two or more) tumor antigens on cells, thereby interrupting the advancement of cancer. As an illustration, the Cancer Facts & Figures 2023 report from the American Cancer Society (ACS), a US-based voluntary health organization, indicated an estimated 609,820 cancer-related fatalities in the USA during 2023. Consequently, the escalating burden of chronic conditions, particularly cancer, is set to boost the need for bispecific MAbs for their effective therapeutic management.

Which Categories Are Covered In The Bi-Specific MAbS Market Segmentation Analysis?

The bi-specific mabs market covered in this report is segmented –

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

Which Market Trends Are Expected To Define The Future Of The Bi-Specific MAbS Market?

Companies operating in the bi-specific MAbs market are increasingly allocating investments to various strategic initiatives, such as collaborations and partnerships, to expand their product portfolios and geographical presence. A strategic collaboration is a cooperative alliance between two or more organizations established to achieve common goals or objectives. For instance, in October 2022, Gilead Sciences, a US-based biopharmaceutical company, and MacroGenics, a US-based biopharmaceutical company, formed an exclusive collaboration to develop MGD024, a bispecific antibody targeting CD123 and CD3 using MacroGenics’ DART platform, along with two other bispecific research programs. This partnership grants Gilead an exclusive option to license MGD024, which holds potential for treating various hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is engineered to minimize cytokine-release syndrome (CRS) and facilitate intermittent dosing, potentially leading to more patient-friendly treatment and improved clinical outcomes for individuals with AML and MDS.

Which Organizations Are At The Forefront Of The Bi-Specific MAbS Market?

Major companies operating in the bi-specific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Parexel, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

Which Geographic Areas Are Driving Strong Demand For The Bi-Specific MAbS Market?

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp

Browse Through More Reports Similar to the Global Bi-Specific MAbS Market 2025, By The Business Research Company

Anti Hypertensive Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Pharmaceutical Api Manufacturing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report

Microbiome Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795